Amarantus BioSciences, Inc. Form SC 13G
November 13, 2012
United states
Securities and exchange commission
WashinGton, d.c. 20549
Schedule 13G
Under the securities exchange act of 1934
AMARANTUS BIOSCIENCES, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
<u>02300Q105</u>
(CUSIP Number)
November 9, 2012
110 (CHILOI ), 2012

(Date of Event which requires filing of this Statement)

q Rule 13d-1(b)			
þ Rule 13d-1(c)			
q Rule 13d-1(d)			

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

The information required in the remainder of this cover page shall not be deemed to be "filed" for purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to \*the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

1.NAME OF REPORTING PERSON					
Ironridge Global IV, Ltd.	Ironridge Global IV, Ltd.				
IRS IDENTIFICATION N	O. OF ABOVE PERSON (EN	TITIES ONLY)			
2.CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) q					
(b) q					
3.SEC USE ONLY					
4. CITIZENSHIP OR PLACE OF ORGANIZATION					
British Virgin Islands					
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:					
	5.	SOLE VOTING POWER			
0* (See Item 4)					
Н	6.	SHARED VOTING POWER			
	7.	SOLE DISPOSITIVE POWER			
14,002,328* (See Item 4)					

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

14,002,328\* (See Item 4)

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES: q

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9:

6.6%\* (See Item 4)

12. TYPE OF REPORTING PERSON

OO

\* Subject to adjustment. (See Item 4)

1.NAME OF REPORTING PERSON
Ironridge Global Partners, LLC
IRS IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
27-4741201
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) q
(b) q
3. SEC USE ONLY
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
5. SOLE VOTING POWER
0* (See Item 4)
6. SHARED VOTING POWER
H* (See Item 4)

	7.	SOLE DISPOSITIVE POWER
0* (See Item 4)		
	8.	SHARED DISPOSITIVE POWER
0* (See Item 4)		
9.	AGGREGATE AMOU	NT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0* (See Item 4)		
10.СНЕСК ВОХ	( IF THE AGGREGATE	AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES: q
11	. PERCEN	NT OF CLASS REPRESENTED BY AMOUNT IN ROW 9:
0%* (See Item 4	)	
	12.	TYPE OF REPORTING PERSON
НС		
*Excludes shares	s owned by Ironridge Glo	obal IV, Ltd. (See Item 4)

1.NAME OF REPORTING PERSON				
Brendan T. O'Neil				
IRS IDENTIFICATION NO	O. OF ABOVE PERSON (EN	ITITIES ONLY)		
2. CHECK THE APPROPR (a) q	RIATE BOX IF A MEMBER	OF A GROUP:		
(b) q				
3. SEC USE ONLY				
4. CITIZENSHIP OR PLAC	CE OF ORGANIZATION			
United States				
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:				
	5.	SOLE VOTING POWER		
0* (See Item 4)				
	6.	SHARED VOTING POWER		
H* (See Item 4)				
	7.	SOLE DISPOSITIVE POWER		
0* (See Item 4)				

	8.	SHARED DISPOSITIVE POWER
0* (See Item 4)		
9. 0* (See Item 4)	AGGREGATE A	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10.CHECK BOX	X IF THE AGGR	EGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES: q
1	1. P	ERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9:
0%* (See Item 4	4)	
	12.	TYPE OF REPORTING PERSON
IN		
* Excludes share	es owned by Ironr	idge Global IV, Ltd. (See Item 4)

	1.	NAME OF REPORTING PERSON	
Richard H. Kreger			
IRS IDENTIFICATION N	O. OF ABOVE PERSON (	ENTITIES ONLY)	
2.CHECK THE APPROPE	RIATE BOX IF A MEMBE	R OF A GROUP:	
(b) q			
3.SEC USE ONLY			
4.CITIZENSHIP OR PLA	CE OF ORGANIZATION		
United States			
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:			
	5.	SOLE VOTING POWER	
0* (See Item 4)			
	6.	SHARED VOTING POWER	
0* (See Item 4)			
	7.	SOLE DISPOSITIVE POWER	
0* (See Item 4)			

	8.	SHARED DISPOSITIVE POWER	
0* (See Item 4)			
9.	AGGREGATE AMOU	UNT BENEFICIALLY OWNED BY EACH REPORTING PERSO	N
0* (See Item 4)			
10.CHECK BOX	X IF THE AGGREGAT	TE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES: q	
11	. PERCE	ENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9:	
0%* (See Item 4	)		
	12.	TYPE OF REPORTING PERSON	
IN			
* Excludes share	es owned by Ironridge G	Global IV, Ltd. (See Item 4)	

1.		NAME OF REPORTING PERSON	
John C. Kirkland			
IRS IDENTIFICATION NO.	OF ABOVE PERSON (E	ENTITIES ONLY)	
2. CHECK THE APPROPRIA	ATE BOX IF A MEMBEI	R OF A GROUP:	
(b) q			
3.SEC USE ONLY			
4. CITIZENSHIP OR PLACE	E OF ORGANIZATION		
United States			
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:			
	5.	SOLE VOTING POWER	
0* (See Item 4)			
(	б.	SHARED VOTING POWER	
H* (See Item 4)			
7		SOLE DISPOSITIVE POWER	
0* (See Item 4)			

	8.	SHARED DISPOSITIVE POWER
0* (See Item 4)		
9. 0* (See Item 4)	AGGREGATE AMOU	INT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10. CHECK BOX	X IF THE AGGREGAT	E AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES: q
11	. PERCE	NT OF CLASS REPRESENTED BY AMOUNT IN ROW 9:
0%* (See Item 4	)	
	12.	TYPE OF REPORTING PERSON
IN		
* Excludes share	es owned by Ironridge G	lobal IV, Ltd. (See Item 4)

	1.	NAME OF REPORTING PERSON	
Keith Coulston			
IRS IDENTIFICATION N	NO. OF ABOVE PERSON (	ENTITIES ONLY)	
2.CHECK THE APPROP	RIATE BOX IF A MEMBE	ER OF A GROUP:	
(b) q			
3.SEC USE ONLY			
4. CITIZENSHIP OR PLA	CE OF ORGANIZATION		
United States			
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:			
	5.	SOLE VOTING POWER	
0* (See Item 4)			
	6.	SHARED VOTING POWER	
0* (See Item 4)			
	7.	SOLE DISPOSITIVE POWER	
0* (See Item 4)			

	8.	SHARED DISPOSITIVE POWER
0* (See Item 4)		
9. 0* (See Item 4)	AGGREGATE AMOU	NT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10.СНЕСК ВОХ	X IF THE AGGREGATI	E AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES: q
11	l. PERCE	NT OF CLASS REPRESENTED BY AMOUNT IN ROW 9:
0%* (See Item 4	)	
	12.	TYPE OF REPORTING PERSON
IN		
* Excludes share	es owned by Ironridge G	lobal IV, Ltd. (See Item 4)

ITEM 1 (a) Name of Issuer:
Amarantus BioSciences, Inc.
(b) Address of Issuer's Principal Executive Offices:
675 Almanor Avenue
Sunnyvale, California 94085
ITEM 2 (a) Name of Person Filing:
This statement is filed by Ironridge Global IV, Ltd. ("IV") with respect to shares of common stock beneficially owned by IV, and by Ironridge Global Partners, LLC ("IGP") and IGP's managing members Brendan T. O'Neil, Richard H. Kreger, John C. Kirkland and Keith Coulston with respect to the shares that may be obtained by IV.
(b) Address of Principal Business Office, or, if None, Residence:
The address of the principal business office of IV is:
Harbour House, Waterfront Drive
Road Town, Tortola
British Virgin Islands VG1110
The address of the principal business office of IGP and Messrs. O'Neil and Coulston is:
One Montgomery Tower

1 Montgomery Street, Suite 2575				
San Francisco, California 94104-4505				
The address of the principal business office of Mr. Kirkland is:				
Palisades Village Center				
881 Alma Real Drive, Suite 305				
Los Angeles, California 90272-3731				
The address of the principal business office of Mr. Kreger is:				
Chrysler Building				
405 Lexington Avenue, 26th Floor				
New York, New York 10174-2699				
(c) Citizenship:				
IV is a British Virgin Islands business company.				
IGP is a Delaware limited liability company.				
Messrs. O'Neil, Kreger, Kirkland and Coulston are United States citizens.				
(d) Title of Class of Securities:				
Common Stock				
(e) CUSIP Number:				

02300Q105

11EM 3: If this Statement if Filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a
qa. Broker or dealer registered under Section 15 of the Exchange Act. qb. Bank as defined in Section 3(a)(6) of the Exchange Act. qc. Insurance company as defined in Section 3(a)(19) of the Exchange Act. qd. Investment company registered under Section 8 of the Investment Company Act. qe. An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E) qf. An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F) qg. A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G) qh. A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the qi. Investment Company Act qj. Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
ITEM 4: Ownership
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned: See item 9 of cover pages.
(b) Percent of class: See item 11 of cover pages.
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote:
(ii) Shared power to vote or to direct the vote:
(iii) Sole power to dispose or to direct the disposition of:

(iv) Shared power to dispose or to direct the disposition of:

See items 5-8 of cover pages.

On November 9, 2012, IV and the issuer settled \$511,310 in accounts payable of the issuer now owned by IV, in exchange for shares of common stock of the issuer. Pursuant to an order approving stipulation for settlement of claims between IV and the issuer, IV is entitled to receive that number of shares with an aggregate value equal to the debt amount plus an 8% third-party agent fee and reasonable attorney fees, divided by 80% of the following: the closing price of the issuer's common stock on the date prior to entry of the order, not to exceed the arithmetic average of the closing bid prices of any five trading days during a period equal to that number of consecutive trading days following the date of initial receipt of shares required for the aggregate trading volume to exceed \$5 million.

IV is prohibited from receiving any shares of common stock that would cause it to be deemed to beneficially own more than 9.99% of the issuer's total outstanding shares at any one time. IV received an initial issuance of common shares, and may be required to return or be entitled to receive shares, based on the calculation summarized in the prior paragraph. For purposes of calculating the percent of class, the reporting persons have assumed that IV would be entitled to 14,002,328 shares based on the \$0.051 closing price on November 9, 2012, and that there were a total of 211,000,000 shares of common stock outstanding immediately prior to the issuance of shares to IV, such that the shares to be issued to and retained by IV would represent approximately 6.6% of the outstanding common stock after such issuance.

In connection with the transaction, IV agreed not to hold any short position in the issuer's common stock, and not to engage in or effect, directly or indirectly, any short sale until at least 180 days after the end of the calculation period.

IV is not a registered broker-dealer or an affiliate of a registered broker-dealer. Voting and dispositive power with respect to shares of common stock owned by IV is exercised by Peter Cooper, Director. However, for so long as IV holds any shares, it is prohibited from, among other actions: (1) voting any shares of issuer common stock owned or controlled by them, exercising any dissenter's rights, executing or soliciting any proxies or seeking to advise or influence any person with respect to any voting securities of the issuer; (2) engaging or participating in any actions or plans that relate to or would result in, among other things, (a) acquiring additional securities of the issuer, alone or together with any other person, which would result in them collectively beneficially owning or controlling, or being deemed to beneficially own or control, more than 9.99% of the total outstanding common stock or other voting securities of the issuer, (b) an extraordinary corporate transaction such as a merger, reorganization or liquidation, (c) a sale or transfer of a material amount of assets, (d) changes in the present board of directors or management of the issuer, (e) material changes in the capitalization or dividend policy of the issuer, (f) any other material change in the issuer's business or corporate structure, (g) actions which may impede the acquisition of control of the issuer by any person or entity, (h) causing a class of securities of the issuer to be delisted, (i) causing a class of equity securities of the issuer to become eligible for termination of registration; or (3) any actions similar to the foregoing.

Each of IGP and Messrs. O'Neil, Kreger, Kirkland and Coulston disclaims beneficial ownership or control of any of the securities covered by this statement. IGP and Messrs. O'Neil, Kreger, Kirkland and Coulston directly own no shares of the issuer. However, by reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, IGP or Messrs. O'Neil, Kreger, Kirkland and Coulston may be deemed to beneficially own or control the shares owned by IV. Messrs. O'Neil, Kreger and Kirkland are each managing directors of IV, and managing directors, members and 30% beneficial owners of IGP. Mr. Coulston is a director, member and 10% beneficial owner of IGP. IGP is a stockholder and beneficial owner of IV.

ITEM 5: Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following box: q

ITEM 6: Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

ITEM 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the

Parent Holding Company or Control Person.
See Exhibit 1.
ITEM 8: Identification and Classification of Members of the Group.
Not Applicable.
ITEM 9: Notice of Dissolution of Group.
Not Applicable.

ITEM 10: Certifications.

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

#### **SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 13, 2012 IRONRIDGE GLOBAL IV, LTD.

By: /s/ Peter Cooper Name: Peter Cooper Its. Director

Dated: November 13, 2012 IRONRIDGE GLOBAL PARTNERS, LLC

By: /s/ Brendan T. O'Neil Name: Brendan T. O'Neil Its. Managing Director

Dated: November 13, 2012 /s/ Brendan T. O'Neil

Brendan T. O'Neil

Dated: November 13, 2012 /s/ Richard H. Kreger

Richard H. Kreger

Dated: November 13, 2012 /s/ John C. Kirkland

# Edgar Filing: Amarantus BioSciences, Inc. - Form SC 13G John C. Kirkland

Dated: November 13, 2012 /s/ Keith Coulston Keith Coulston

EXHIBIT INDEX TO SCHEI	JULE	-13G
------------------------	------	------

### EXHIBIT 1

Exhibit Stating Identity of Relevant Subsidiary per Item 7 of Schedule 13G.

## EXHIBIT 2

Joint Filing Agreement among Ironridge Global IV, Ltd., Ironridge Global Partners, LLC, Brendan T. O'Neil, Richard H. Kreger, John C. Kirkland and Keith Coulston.

# Exhibit 1

Ironridge Global IV, Ltd. is a subsidiary of Ironridge Global Partners, LLC.

#### Exhibit 2

#### JOINT FILING AGREEMENT

This Joint Filing Agreement, entered into and effective as of November 13, 2012, is made by and among Ironridge Global IV, Ltd., a British Virgin Islands business company, Ironridge Global Partners, LLC, a Delaware limited liability company, Brendan T. O'Neil, Richard H. Kreger, John C. Kirkland and Keith Coulston pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

Each of the filers hereby acknowledges and agrees that the foregoing statement on Schedule 13G is filed on behalf of each of the filers and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the filers without the necessity of filing additional joint filing agreements. Each filer acknowledges that such filer shall be responsible for the timely filing of such amendments and for the completeness and accuracy of the information concerning such filer contained therein, but shall not be responsible for the completeness and accuracy of the information concerning any of the other filers, except to the extent that such filer knows or has reason to believe that such information is inaccurate.

This Joint Filing Agreement may be executed in any number of counterparts and all of such counterparts taken together shall constitute one and the same instrument.

This Joint Filing Agreement may be terminated by any of the filers upon written notice to the other filers.

Dated: November 13, 2012 | IRONRIDGE GLOBAL IV, LTD.

By: /s/ Peter Cooper Name: Peter Cooper Its. Director

Dated: November 13, 2012 IRONRIDGE GLOBAL PARTNERS, LLC

By: /s/ Brendan T. O'Neil Name: Brendan T. O'Neil Its. Managing Director

Dated: November 13, 2012 /s/ Brendan T. O'Neil

Brendan T. O'Neil

Dated: November 13, 2012 /s/ Richard H. Kreger

Richard H. Kreger

Dated: November 13, 2012 /s/ John C. Kirkland

John C. Kirkland

Dated: November 13, 2012 /s/ Keith Coulston

Keith Coulston